Literature DB >> 8536514

Gallbladder stone recurrence after medical treatment. Do gallstones recur true to type?

S P Pereira1, S H Hussaini, C Kennedy, R H Dowling.   

Abstract

Medical treatments that dissolve or remove gallbladder stones but leave the gallbladder in situ have the disadvantage of gallstone recurrence. Little is known about the composition of recurrent stones or whether they recur true to type. In 21 patients with recurrent stones detected 5-74 months (mean +/- SEM, 26 +/- 4 months) after being rendered stone-free with dissolution therapy (N = 15) or percutaneous cholecystolithotomy (N = 6), we compared pretreatment and postrecurrence gallstone number, maximum gallstone attenuation scores measured by computed tomography (CT) and, in 13, the dissolvability of the recurrent stones with oral bile acids +/- extracorporeal shock-wave lithotripsy. Before treatment, five patients had solitary and 16 had multiple stones but on recurrence, the gallstones differed in number from the primary stones in 10 of the 21 patients. As a result of patient selection, before dissolution, the primary stones were all radiolucent with maximum CT scores of < 100 Hounsfield units (HU) (mean 45, range 10-84 HU). On recurrence, the stones were again CT-lucent in 13 of the 15 patients but were CT-dense in the remaining two (118 and 176 HU). Initially, all six patients treated by percutaneous cholecystolithotomy had radio-opaque stones, with a mean CT score of 459 (range 100-969) HU. However, on recurrence, only one had calcified stones (HU 140); the remaining five had CT-lucent stones (16-98 HU, P < 0.05). Of the 13 patients whose recurrent, plain x-ray-lucent and CT-lucent stones were treated with oral bile acids +/- lithotripsy, 12 (92%) showed evidence of gallstone dissolution. We conclude that gallbladder stones do not recur true to type in up to two thirds of patients. However, irrespective of original gallstone composition, recurrent stones are usually radio- and CT-lucent, presumed cholesterol-rich, and therefore potentially dissolvable with oral bile acids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536514     DOI: 10.1007/bf02220443

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  57 in total

1.  Evaluation of radiographic lucency or opaqueness of gallstones as a means of identifying cholesterol or pigment stones. Correlation of lucency or opaqueness with calcium and mineral.

Authors:  B W Trotman; E J Petrella; R D Soloway; H M Sanchez; T A Morris; W T Miller
Journal:  Gastroenterology       Date:  1975-06       Impact factor: 22.682

2.  Visibility of gallstone fragments at US and fluoroscopy: implications for monitoring gallstone lithotripsy.

Authors:  B S Garra; W J Davros; E E Lack; S C Horii; P M Silverman; R K Zeman
Journal:  Radiology       Date:  1990-02       Impact factor: 11.105

3.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-08       Impact factor: 3.199

4.  Persistence of symptoms after gall bladder clearance with cholecystolithotripsy.

Authors:  S H Lee; H J Burhenne
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

5.  Computed tomography in predicting gall stone solubility: a prospective trial.

Authors:  A Caroli; G Del Favero; F Di Mario; F Spigariol; P Scalon; T Meggiato; C Zambelli; R Naccarato
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

6.  Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible?

Authors:  J H Iser; G M Murphy; R H Dowling
Journal:  Gut       Date:  1977-01       Impact factor: 23.059

7.  Recurrent gallstone formation after successful extracorporeal shock-wave lithotripsy.

Authors:  H T Schneider; J Benninger; U Rabes; N Madani; A May; E G Hahn; C Ell
Journal:  Am J Gastroenterol       Date:  1993-09       Impact factor: 10.864

8.  Increased blood levels of methyl tert-butyl ether but not of ethyl propionate during instillation with contact gallstone dissolution agents in the pig.

Authors:  O Esch; C D Schteingart; D Pappert; D Kirby; R Streich; A F Hofmann
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

9.  Recurrence and re-recurrence of gall stones after medical dissolution: a longterm follow up.

Authors:  L D O'Donnell; K W Heaton
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

10.  Abnormal gallbladder emptying in a subgroup of patients with gallstones.

Authors:  I S Pomeranz; E A Shaffer
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

View more
  2 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.